Compugen to Present New Clinical Data at SITC 2024
Compugen (Nasdaq: CGEN) has announced that new clinical data will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 8-10, 2024. The presentation will focus on the anti-tumor activity and safety of a triple combination therapy involving COM701, COM902, and pembrolizumab in heavily pre-treated patients with platinum-resistant ovarian cancer.
The poster presentation, titled "Triple blockade of DNAM-1axis with COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows preliminary antitumor activity in patients with platinum resistant ovarian cancer, interim results of Phase I trial," will be delivered by Dr. Oladapo Yeku, a Medical Oncologist from Massachusetts General Hospital, on Friday, November 8, 2024. The abstract number for this presentation is 985.
Compugen (Nasdaq: CGEN) ha annunciato che nuovi dati clinici saranno presentati alla 39a Assemblea Annuale della Society for Immunotherapy of Cancer (SITC) a Houston, Texas, dal 8 al 10 novembre 2024. La presentazione si concentrerà sull'attività anti-tumorale e sulla sicurezza di una terapia combinata tripletta che coinvolge COM701, COM902 e pembrolizumab in pazienti con cancro ovarico resistente al platino e con un elevato numero di trattamenti precedenti.
La presentazione poster, intitolata "Blocco triplo dell'asse DNAM-1 con COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab mostra attività antitumorale preliminare in pazienti con cancro ovarico resistente al platino, risultati intermedi della fase I della sperimentazione," sarà tenuta dal Dr. Oladapo Yeku, Oncologo Medico del Massachusetts General Hospital, venerdì 8 novembre 2024. Il numero dell'abstract per questa presentazione è 985.
Compugen (Nasdaq: CGEN) ha anunciado que nuevos datos clínicos serán presentados en la 39ª Reunión Anual de la Society for Immunotherapy of Cancer (SITC) en Houston, Texas, del 8 al 10 de noviembre de 2024. La presentación se centrará en la actividad anti-tumoral y seguridad de una terapia combinada triple que involucra a COM701, COM902 y pembrolizumab en pacientes con cáncer de ovario resistente al platino y con tratamiento previo intensivo.
La presentación del póster, titulada "Bloqueo triple del eje DNAM-1 con COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab muestra actividad antitumoral preliminar en pacientes con cáncer de ovario resistente al platino, resultados intermedios del ensayo de fase I," será realizada por el Dr. Oladapo Yeku, Oncólogo Médico del Massachusetts General Hospital, el viernes 8 de noviembre de 2024. El número de abstract para esta presentación es 985.
Compugen (Nasdaq: CGEN)는 2024년 11월 8일부터 10일까지 텍사스 휴스턴에서 열리는 제39회 암 면역 요법 학회(SITC) 연례 회의에서 새로운 임상 데이터를 발표할 것이라고 발표했습니다. 발표는 COM701, COM902 및 pembrolizumab을 포함하는 삼중 조합 요법의 항종양 활성 및 안전성에 초점을 맞추며, 백금 저항성 난소암으로 강도 높은 치료를 받은 환자들을 대상으로 합니다.
"COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab의 DNAM-1 축의 삼중 차단은 백금 저항성 난소암 환자에서 항종양 활성의 초기 결과를 보여줍니다. 임상 1상 시험의 중간 결과"라는 제목의 포스터 발표는 매사추세츠 종합 병원의 암 전문의 올라도포 예쿠 박사에 의해 2024년 11월 8일 금요일에 진행됩니다. 이 발표의 초록 번호는 985입니다.
Compugen (Nasdaq: CGEN) a annoncé que de nouvelles données cliniques seront présentées lors de la 39ème Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC) à Houston, Texas, du 8 au 10 novembre 2024. La présentation portera sur l'activité anti-tumorale et la sécurité d'une thérapie combinée triple impliquant COM701, COM902 et pembrolizumab chez des patients ayant bénéficié de nombreux traitements préalables pour un cancer de l'ovaire résistant au platine.
La présentation de l'affiche, intitulée "Blocage triple de l'axe DNAM-1 avec COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab montre une activité antitumorale préliminaire chez des patients atteints de cancer de l'ovaire résistant au platine, résultats intermédiaires de l'essai de Phase I," sera présentée par le Dr Oladapo Yeku, oncologue médical du Massachusetts General Hospital, le vendredi 8 novembre 2024. Le numéro de l'abstract pour cette présentation est 985.
Compugen (Nasdaq: CGEN) hat angekündigt, dass neue klinische Daten auf dem 39. Jahrestreffen der Society for Immunotherapy of Cancer (SITC) in Houston, Texas, vom 8. bis 10. November 2024 präsentiert werden. Der Fokus der Präsentation liegt auf der anti-tumoralen Aktivität und Sicherheit einer dreifachen Kombinationstherapie, die COM701, COM902 und Pembrolizumab bei stark vorbehandelten Patienten mit platinresistentem Ovarialkarzinom umfasst.
Die Posterpräsentation mit dem Titel "Dreifachblockade der DNAM-1-Achse mit COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + Pembrolizumab zeigt vorläufige anti-tumorale Aktivität bei Patienten mit platinresistentem Ovarialkarzinom, vorläufige Ergebnisse der Phase-I-Studie," wird von Dr. Oladapo Yeku, einem medizinischen Onkologen des Massachusetts General Hospital, am Freitag, den 8. November 2024, gehalten. Die Abstract-Nummer für diese Präsentation ist 985.
- Presentation of new clinical data at a major cancer immunotherapy conference
- Preliminary anti-tumor activity observed in triple combination therapy
- Targeting heavily pre-treated patients with platinum-resistant ovarian cancer
- None.
HOLON,
Poster presentation details:
Abstract Title: Triple blockade of DNAM-1axis with COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows preliminary antitumor activity in patients with platinum resistant ovarian cancer, interim results of Phase I trial
Abstract number: 985
Presenter: Dr. Oladapo Yeku, Medical Oncologist, Massachusetts General Hospital
Date: Friday, November 8, 2024
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-new-clinical-data-at-sitc-2024-302268683.html
SOURCE Compugen Ltd.
FAQ
What new clinical data will Compugen (CGEN) present at SITC 2024?
When and where will Compugen (CGEN) present its clinical data at SITC 2024?
Who will present Compugen's (CGEN) clinical data at SITC 2024?
What is the abstract number for Compugen's (CGEN) presentation at SITC 2024?
